Basilea Pharmaceutica Ltd.'s licensing partner Astellas Pharma Inc. won the favor of the FDA's Anti-Infective Drugs Advisory Committee for the antifungal isavuconazole, achieving a slam-dunk vote of 8-0 to recommend approval in the invasive aspergillosis indication, though the panel's balloting proved less certain about the rarer invasive mucormycosis: 8-2 in favor, with one abstention.